About Hyaluronidase-1
Hyaluronidase-1 (HYAL1) is a protein
from Homo sapiens identified by UniProt accession
Q12794, 435 residues long.
MolForge cross-references it against 0 known binders and
92 disease associations.
Target properties
| Protein name | Hyaluronidase-1 |
|---|
| UniProt accession | Q12794 |
|---|
| Gene | HYAL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 435 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (92)
Diseases linked to this target (Open Targets).
- Hyaluronidase deficiency · score 0.70
- mucopolysaccharidosis type 9 · score 0.63
- mucopolysaccharidosis · score 0.46
- schizophrenia · score 0.17
- neuroticism measurement · score 0.12
- wellbeing measurement · score 0.12
- cutaneous melanoma · score 0.10
- neoplasm · score 0.09
- depressive symptom measurement · score 0.08
- mean platelet volume · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q12794-F1 | alphafold | PREDICTED | 94.02 | — |
Amino-acid sequence (435 residues)
MAAHLLPICA LFLTLLDMAQ GFRGPLLPNR PFTTVWNANT QWCLERHGVD VDVSVFDVVA NPGQTFRGPD MTIFYSSQLG TYPYYTPTGE PVFGGLPQNA SLIAHLARTF QDILAAIPAP DFSGLAVIDW EAWRPRWAFN WDTKDIYRQR SRALVQAQHP DWPAPQVEAV AQDQFQGAAR AWMAGTLQLG RALRPRGLWG FYGFPDCYNY DFLSPNYTGQ CPSGIRAQND QLGWLWGQSR ALYPSIYMPA VLEGTGKSQM YVQHRVAEAF RVAVAAGDPN LPVLPYVQIF YDTTNHFLPL DELEHSLGES AAQGAAGVVL WVSWENTRTK ESCQAIKEYM DTTLGPFILN VTSGALLCSQ ALCSGHGRCV RRTSHPKALL LLNPASFSIQ LTPGGGPLSL RGALSLEDQA QMAVEFKCRC YPGWQAPWCE RKSMW
Explore Hyaluronidase-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets